FACT SHEET FOR HEALTHCARE PROVIDERS
EMERGENCY USE AUTHORIZATION (EUA) OF SOTROVIMAB

AUTHORIZED USE
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

LIMITATIONS OF AUTHORIZED USE
- Sotrovimab is not authorized for treatment of mild-to-moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to these drugs and regional variant frequency.
  - FDA’s determination and any updates will be available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.
- Sotrovimab is not authorized for use in the following patient populations:
  - Adults or pediatric patients who are hospitalized due to COVID-19, OR
  - Adults or pediatric patients who require oxygen therapy and/or respiratory support due to COVID-19, OR
  - Adults or pediatric patients who require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 in those patients on chronic oxygen.
- Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID-19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

RECENT MAJOR CHANGES
- Limitations of Authorized Use - updated authorization for those likely to have been infected with or have been exposed to a susceptible SARS-CoV-2 variant

1 FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility [see Microbiology/Resistance Information (15)], and CDC regional variant frequency data available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
Dosage and Administration (Box and Sections 2.2 and 2.4): updated intravenous infusion time
Revised 02/2022

Overall Safety Summary, Clinical Trials Experience (Section 6.1, 14.2 and 18): addition of COMET-TAIL safety, PK, and efficacy data
Revised 02/2022

Microbiology/Resistance Information, Antiviral Resistance (Section 15): addition of information on susceptibility of SARS-CoV-2 variants to sotrovimab
Revised 02/2022

Overall Safety Summary, Post-Authorization Experience (Section 6.2): addition of anaphylaxis
Revised 11/2021

Dosage and Administration, Dose Preparation and Administration (Section 2.4): addition of 5% Dextrose injection and updated storage of diluted solution of sotrovimab
Revised 09/2021

Clinical Trial Results and Supporting Data for EUA (Section 18): updated with efficacy results for the full population
Revised 09/2021

Sotrovimab has been authorized by FDA for the emergency use described above.

Sotrovimab is not FDA-approved for this use.

Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

This EUA is for the use of the unapproved product sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-COV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death [see Limitations of Authorized Use].

The following medical conditions or other factors may place adults and pediatric patients (12 to 17 years of age weighing at least 40 kg) at higher risk for progression to severe COVID-19:

- Older age (for example ≥65 years of age)
- Obesitiy or being overweight (for example, adults with BMI >25 kg/m², or if 12 to 17 years of age, have BMI ≥85th percentile for their age and gender based on CDC growth charts, [https://www.cdc.gov/growthcharts/clinical_charts.htm])
• Pregnancy
• Chronic kidney disease
• Diabetes
• Immunosuppressive disease or immunosuppressive treatment
• Cardiovascular disease (including congenital heart disease) or hypertension
• Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
• Sickle cell disease
• Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
• Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19, and authorization of sotrovimab under the EUA is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19, see the CDC website: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Healthcare providers should consider the benefit-risk for an individual patient.


**Sotrovimab must be administered after dilution by intravenous (IV) infusion.** See the Full EUA Prescribing Information for complete dosage, administration, and preparation instructions.

• The authorized dosage for sotrovimab is 500 mg administered as a single IV infusion as soon as possible after a positive viral test for SARS-CoV-2 and within 7 days of symptom onset [see Dosage and Administration (2.2) and Clinical Trial Results and Supporting Data for EUA (18)].

• Sotrovimab is available as a concentrated solution and **must be diluted** prior to IV infusion.

• Administer 500 mg of sotrovimab by IV infusion over 15 minutes for 50-mL infusion bag or 30 minutes for 100-mL infusion bag.
Clinically monitor patients during infusion and observe patients for at least 1 hour after infusion is complete.

Sotrovimab may only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary.

The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory reporting of all SERIOUS ADVERSE EVENTS and MEDICATION ERRORS potentially related to sotrovimab within 7 calendar days from the healthcare provider’s awareness of the event. See Sections 8 and 9 of the Full EUA Fact Sheet for reporting requirements.

Patients treated with sotrovimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines.

The authorized dosage may be updated as additional data from clinical trials becomes available.

For information on clinical trials that are testing the use of sotrovimab in COVID-19, please see www.clinicaltrials.gov.

Contraindications

Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.

Dosing

See Full Fact Sheet for Healthcare Providers for information on dosing [see Dosage and Administration (2)].

Preparation and Administration

See Full Fact Sheet for Healthcare Providers for information on preparation and administration [see Dosage and Administration (2.4)].

Storage

Refrigerate unopened vials at 2°C to 8°C (36°F to 46°F) in original carton. Do not freeze or shake. Protect from light.

Warnings

There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.
Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab [see Full EUA Prescribing Information, Overall Safety Summary (6.1)]. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.

Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.

Signs and symptoms of infusion-related reactions may include:

- fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (e.g., pre-syncope, syncope), dizziness, and diaphoresis.

If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care. Clinically monitor patients for at least 1 hour after completion of the infusion for signs and symptoms of hypersensitivity.

Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.

Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration

Clinical worsening of COVID-19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19.

Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19

Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID-19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in the following patient populations [see Limitations of Authorized Use]:

- Adults or pediatric patients who are hospitalized due to COVID-19, OR
- Adults or pediatric patients who require oxygen therapy and/or respiratory support due to
COVID-19, OR

- Adults or pediatric patients who require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 in those patients on chronic oxygen.

**Side Effects**

Adverse events have been reported with sotrovimab [see Full EUA Prescribing Information, Overall Safety Summary (6.1)].

Additional adverse events associated with sotrovimab, some of which may be serious, may become apparent with more widespread use.

**INSTRUCTIONS FOR HEALTHCARE PROVIDERS**

As the healthcare provider, you must communicate to your patient or parent/caregiver, as age appropriate, information consistent with the “Fact Sheet for Patients, Parents, and Caregivers” (and provide a copy of the Fact Sheet) prior to the patient receiving sotrovimab, including:

- FDA has authorized the emergency use of sotrovimab for treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death [see Limitations of Authorized Use].
- The patient or parent/caregiver has the option to accept or refuse sotrovimab.
- The significant known and potential risks and benefits of sotrovimab and the extent to which such risks and benefits are unknown.
- Information on available alternative treatments and the risks and benefits of those alternatives, including clinical trials.
- Patients treated with sotrovimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines.

For information on clinical trials that are testing the use of sotrovimab for COVID-19, please see [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

**MANDATORY REQUIREMENTS FOR ADMINISTRATION OF SOTROVIMAB UNDER EMERGENCY USE AUTHORIZATION**

In order to mitigate the risks of using this unapproved product under the EUA and to optimize the potential benefit of sotrovimab, the following steps are required. Use of sotrovimab under this EUA is limited to the following (all requirements must be met):

1. Treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing,
and who are at high risk for progression to severe COVID-19, including hospitalization or death [see Limitations of Authorized Use].

2. As the healthcare provider, communicate to your patient or parent/caregiver information consistent with the “Fact Sheet for Patients, Parents, and Caregivers” prior to the patient receiving sotrovimab. Healthcare providers (to the extent practicable given the circumstances of the emergency) must document in the patient’s medical record that the patient/caregiver has been:
   a. Given the “Fact Sheet for Patients, Parents, and Caregivers”,
   b. Informed of alternatives to receiving authorized sotrovimab, and
   c. Informed that sotrovimab is an unapproved drug that is authorized for use under this Emergency Use Authorization.

3. Patients with known hypersensitivity to any ingredient of sotrovimab must not receive sotrovimab.

4. The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory reporting of all serious adverse events* and medication errors potentially related to sotrovimab within 7 calendar days from the healthcare provider’s awareness of the event, using FDA Form 3500 (for information on how to access this form, see below). The FDA requires that such reports, using FDA Form 3500, include the following:
   • Patient demographics and baseline characteristics (e.g., patient identifier, age or date of birth, gender, weight, ethnicity, and race)
   • A statement "Sotrovimab use for COVID-19 under Emergency Use Authorization (EUA)” under the “Describe Event, Problem, or Product Use/Medication Error” heading
   • Information about the serious adverse event or medication error (e.g., signs and symptoms, test/laboratory data, complications, timing of drug initiation in relation to the occurrence of the event, duration of the event, treatments required to mitigate the event, evidence of event improvement/disappearance after stopping or reducing the dosage, evidence of event reappearance after reintroduction, clinical outcomes)
   • Patient’s preexisting medical conditions and use of concomitant products
   • Information about the product (e.g., dosage, route of administration, NDC #)

5. Submit adverse event and medication error reports, using Form 3500, to FDA MedWatch using one of the following methods:
   • Complete and submit the report online: www.fda.gov/medwatch/report.htm
   • Complete and submit a postage-paid FDA Form 3500 (https://www.fda.gov/media/76299/download) and return by:
Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
Fax to 1-800-FDA-0178, or
- Call 1-800-FDA-1088 to request a reporting form
- In addition, please provide a copy of all FDA MedWatch forms to:
  GlaxoSmithKline, Global Safety
  Fax: 919-287-2902
  Email: WW.GSKAEReportingUS@gsk.com
  Or call the GSK COVID Contact Center at 1-866-GSK-COVID (866-475-2684) to report adverse events.

6. The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory responses to requests from FDA for information about adverse events and medication errors following receipt of sotrovimab.

*Serious Adverse Events are defined as:
- death;
- a life-threatening adverse event;
- inpatient hospitalization or prolongation of existing hospitalization;
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
- a congenital anomaly/birth defect;
- other important medical event, which may require a medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly.

7. OTHER REPORTING REQUIREMENTS
- Healthcare facilities and providers will report therapeutics information and utilization data as directed by the U.S. Department of Health and Human Services.

APPROVED AVAILABLE ALTERNATIVES

Veklury (remdesivir) is FDA-approved for the treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, who are not hospitalized and have mild-to-moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Veklury is administered via IV infusion for a total treatment duration of 3 days. Although Veklury is an approved alternative treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including
hospitalization or death. FDA does not consider Veklury to be an adequate alternative to sotrovimab for this authorized use because it may not be feasible or practical for certain patients (e.g., it requires a 3-day treatment duration).

Additional information on COVID-19 treatments can be found at http://www.covid19treatmentguidelines.nih.gov/. The healthcare provider should visit https://clinicaltrials.gov/ to determine whether the patient may be eligible for enrollment in a clinical trial.

AUTHORITY FOR ISSUANCE OF THE EUA

The Secretary of the Department of Health and Human Services (HHS) has declared a public health emergency that justifies the emergency use of drugs and biological products during the COVID-19 pandemic. In response, the FDA has issued this EUA, as requested by GlaxoSmithKline, for the unapproved product, sotrovimab, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-COV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.2 As a healthcare provider, you must comply with the mandatory requirements of this EUA (see above).

Although limited scientific information is available, based on the totality of the scientific evidence available to date, it is reasonable to believe that sotrovimab may be effective for the treatment of mild-to-moderate COVID-19 in certain at-risk patients as specified in this Fact Sheet. You may be contacted and asked to provide information to help with the assessment of the use of the product during this emergency.

This EUA for sotrovimab will end when the Secretary determines that the circumstances justify the EUA no longer exist or when there is a change in the approval status of the product such that an EUA may no longer be needed.

CONTACT INFORMATION

For additional information visit www.sotrovimabinfo.com

If you have questions, please call the GSK COVID Contact Center at 1-866-GSK-COVID (866-475-2684).

END SHORT VERSION FACT SHEET

Long Version Begins on Next Page

---

2 The healthcare provider should visit https://clinicaltrials.gov/ to determine whether there is an active clinical trial for the product in this disease/condition and whether enrollment of the patient(s) in a clinical trial is more appropriate than product use under this EUA.
FULL EUA PRESCRIBING INFORMATION

FULL EUA PRESCRIBING INFORMATION: CONTENTS*

1 AUTHORIZED USE
2 DOSAGE AND ADMINISTRATION
   2.1 Patient Selection
   2.2 Dosage
   2.3 Dosage Adjustment in Specific Populations
   2.4 Dose Preparation and Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
   5.1 Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions
   5.2 Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration
   5.3 Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19
6 OVERALL SAFETY SUMMARY
   6.1 Clinical Trials Experience
   6.2 Post-Authorization Experience
7 PATIENT MONITORING RECOMMENDATIONS
8 ADVERSE REACTIONS AND MEDICATION ERRORS REPORTING REQUIREMENTS AND INSTRUCTIONS
9 OTHER REPORTING REQUIREMENTS
10 DRUG INTERACTIONS
11 USE IN SPECIFIC POPULATIONS
   11.1 Pregnancy
   11.2 Lactation
   11.3 Pediatric Use
   11.4 Geriatric Use
   11.5 Renal Impairment
   11.6 Hepatic Impairment
12 OVERDOSE
13 PRODUCT DESCRIPTION
14 CLINICAL PHARMACOLOGY
   14.1 Mechanism of Action
   14.2 Pharmacokinetics
15 MICROBIOLOGY/RESISTANCE INFORMATION
16 NONCLINICAL TOXICOLOGY
17 ANIMAL PHARMACOLOGIC AND EFFICACY DATA
18 CLINICAL TRIAL RESULTS AND SUPPORTING DATA FOR EUA
19 HOW SUPPLIED/STORAGE AND HANDLING
20 PATIENT COUNSELING INFORMATION
21 CONTACT INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
1 AUTHORIZED USE

Sotrovimab is authorized for use under an Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death [see Clinical Trial Results and Supporting Data for EUA (18)].

LIMITATIONS OF AUTHORIZED USE

• Sotrovimab is not authorized for treatment of mild-to-moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to these drugs and regional variant frequency.
  ○ FDA’s determination and any updates will be available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.3

• Sotrovimab is not authorized for use in the following patient populations:
  ○ Adults or pediatric patients who are hospitalized due to COVID-19, OR
  ○ Adults or pediatric patients who require oxygen therapy and/or respiratory support due to COVID-19, OR
  ○ Adults or pediatric patients who require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 in those patients on chronic oxygen.

• Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID-19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation [see Warnings and Precautions (5.2)].

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection

Sotrovimab should be administered as soon as possible after a positive viral test for SARS-CoV-2 and within 7 days of symptom onset in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death [see Authorized Use (1) and Clinical Trial Results and Supporting Data for EUA (18)].

The following medical conditions or other factors may place adults and pediatric patients (12 to

3 FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility [see Microbiology/Resistance Information (15)], and CDC regional variant frequency data available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
17 years of age weighing at least 40 kg) at higher risk for progression to severe COVID-19:

- Older age (for example, ≥65 years of age)
- Obesity or being overweight (for example, adults with BMI >25 kg/m², or if 12 to 17, have BMI ≥85th percentile for their age and gender based on CDC growth charts, [https://www.cdc.gov/growthcharts/clinical_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm))
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19, and authorization of sotrovimab under the EUA is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19, see the CDC website: [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html). Healthcare providers should consider the benefit-risk for an individual patient.

### 2.2 Dosage

The dosage in adults and pediatric patients (12 years of age and older weighing at least 40 kg) is 500 mg of sotrovimab administered as a single IV infusion. Sotrovimab should be given as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset.

- Sotrovimab is available as a concentrated solution and **must be diluted** prior to IV infusion.
- Administer 500 mg of sotrovimab by IV infusion over 15 minutes for 50-mL infusion bag or 30 minutes for 100-mL infusion bag.
- Clinically monitor patients during infusion and observe patients for at least 1 hour after infusion is complete.
2.3 Dosage Adjustment in Specific Populations

Pregnancy or Lactation

No dosage adjustment is recommended in pregnant or lactating women [see Use in Specific Populations (11.1, 11.2)].

Pediatric Use

No dosage adjustment is recommended in pediatric patients who weigh at least 40 kg and are 12 years of age and older. Sotrovimab is not authorized for patients under 12 years of age or pediatric patients weighing less than 40 kg [see Use in Specific Populations (11.3)].

Geriatric Use

No dosage adjustment is recommended in geriatric patients [see Use in Specific Populations (11.4)].

Renal Impairment

No dosage adjustment is recommended in patients with renal impairment [see Use in Specific Populations (11.5)].

2.4 Dose Preparation and Administration

Preparation

Sotrovimab is supplied in a single-dose vial and must be diluted prior to IV infusion.

Sotrovimab infusion solution should be prepared by a qualified healthcare professional using aseptic technique.

- Gather the materials for preparation:
  - Polyvinyl chloride (PVC) or polyolefin (PO), sterile, prefilled 50-mL or 100-mL infusion bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection, and
  - One vial of sotrovimab (500 mg/8 mL).
- Remove one vial of sotrovimab from refrigerated storage and allow to equilibrate to room temperature, protected from light, for approximately 15 minutes.
- Inspect the vial of sotrovimab visually for particulate matter and discoloration prior to administration. Should either be observed, the solution must be discarded and fresh solution prepared. Sotrovimab is a clear, colorless or yellow to brown solution.
- Gently swirl the vial several times before use without creating air bubbles. Do not shake the vial.
- Withdraw 8 mL of sotrovimab from one vial and inject into the prefilled infusion bag.
- Discard any product remaining in the vial.
- Prior to the infusion, gently rock the infusion bag back and forth by hand 3 to 5 times. Do
not invert the infusion bag. Avoid forming air bubbles.

- This product is preservative-free; therefore, the diluted infusion solution should be administered immediately. If immediate administration is not possible, store the diluted solution of sotrovimab up to 6 hours at room temperature (up to 25°C [up to 77°F]) or refrigerated up to 24 hours (2°C to 8°C [36°F to 46°F]).

Administration

Sotrovimab infusion solution should be administered by a qualified healthcare professional [see Warnings and Precautions (5.1)].

Sotrovimab may only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary [see Warnings and Precautions (5.1)].

- Gather the materials for infusion via infusion pump or gravity:
  - Polyvinyl chloride (PVC) or polyolefin (PO) infusion set, and
  - Use of a 0.2 micron polyethersulfone (PES) filter is strongly recommended.
- Attach the infusion set to the IV bag using standard bore tubing.
- Prime the infusion set.
- Administer the entire infusion solution in the bag over 15 minutes for 50-mL infusion bag or 30 minutes for 100-mL infusion bag. Due to potential overfill of prefilled saline bags, the entire infusion solution in the bag should be administered to avoid underdosage.
- Do not administer as an IV push or bolus.
- The prepared infusion solution should not be administered simultaneously with any other medication. The compatibility of sotrovimab with IV solutions and medications other than 0.9% Sodium Chloride Injection and 5% Dextrose Injection is not known.
- Once infusion is complete, flush the tubing with 0.9% Sodium Chloride or 5% Dextrose to ensure delivery of the required dose.
- If the infusion must be discontinued due to an infusion reaction, discard unused product.
- Clinically monitor patients during infusion and observe patients for at least 1 hour after infusion is complete.

3 DOSAGE FORMS AND STRENGTHS

Sotrovimab is a sterile, preservative-free, clear, colorless or yellow to brown solution available as:

- Injection: 500-mg/8-mL (62.5-mg/mL) solution in a single-dose vial.
4 CONTRAINDICATIONS
Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.

5 WARNINGS AND PRECAUTIONS
There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.

5.1 Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab [see Overall Safety Summary (6.1)]. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.

Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.

Signs and symptoms of infusion-related reactions may include [see Overall Safety Summary (6.1)]:
- fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (e.g., pre-syncope, syncope), dizziness, and diaphoresis.

If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care. Clinically monitor patients for at least 1 hour after completion of the infusion for signs and symptoms of hypersensitivity.

Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.

5.2 Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration
Clinical worsening of COVID-19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19.

5.3 Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19
Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to
COVID-19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in the following patient populations [see Limitations of Authorized Use]:

- Adults or pediatric patients who are hospitalized due to COVID-19, OR
- Adults or pediatric patients who require oxygen therapy and/or respiratory support due to COVID-19, OR
- Adults or pediatric patients who require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 in those patients on chronic oxygen.

6 OVERALL SAFETY SUMMARY

6.1 Clinical Trials Experience

The safety of sotrovimab in subjects with mild-to-moderate COVID-19 (subjects with COVID-19 symptoms who are not hospitalized) is based on analyses from COMET-ICE, a Phase 1/2/3 trial, and COMET-TAIL, a Phase 3 trial [see Clinical Trial Results and Supporting Data for EUA (18)].

In COMET-ICE, subjects received a single 500-mg infusion of sotrovimab (n = 523) or placebo (n = 526). Two subjects experienced treatment interruptions due to infusion site extravasation; infusion was completed for each. In COMET-TAIL, subjects received a single 500-mg IV infusion of sotrovimab (n = 393).

Infusion-Related Reactions Including Hypersensitivity

Infusion-related reactions, including immediate hypersensitivity reactions, were observed in 1% of subjects treated with sotrovimab and 1% of subjects treated with placebo in COMET-ICE and in <1% of subjects treated with IV sotrovimab in COMET-TAIL. Reported events that started within 24 hours of study treatment were pyrexia, chills, dizziness, dyspnea, pruritus, rash, and infusion-related reactions; all events were Grade 1 (mild) or Grade 2 (moderate).

One case of anaphylaxis was reported following sotrovimab infusion in a study in hospitalized subjects; the infusion was immediately discontinued, and the subject received epinephrine. The event resolved but recurred within 2 hours; the subject received another dose of epinephrine and improved with no additional reactions. Other serious infusion-related reactions (including immediate hypersensitivity reactions) reported following sotrovimab infusion in the hospitalized study included Grade 3 (serious) or Grade 4 (life-threatening) bronchospasm and shortness of breath. These events were also reported following infusion of placebo. Sotrovimab is not authorized for use in subjects hospitalized due to COVID-19 [see Warnings and Precautions (5.1, 5.3)].

Hypersensitivity adverse reactions (i.e., adverse events assessed as causally related) were observed in 2% of subjects treated with sotrovimab and 1% of subjects treated with placebo in COMET-ICE and in <1% of subjects treated with sotrovimab in COMET-TAIL. All were
Grade 1 (mild) or Grade 2 (moderate), and none of the reactions in either trial led to permanent discontinuation of the infusions. One reaction led to pausing of the infusion [see Warnings and Precautions (5.1)].

Common Adverse Events
The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.

6.2 Post-Authorization Experience
The following adverse reactions have been identified during post-authorization use of sotrovimab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders
Anaphylaxis [see Contraindications (4), Warnings and Precautions (5.1)].

7 PATIENT MONITORING RECOMMENDATIONS
Clinically monitor patients during dose administration and observe patients for at least 1 hour after IV infusion is complete [see Warnings and Precautions (5.1, 5.2) and Overall Safety Summary (6.1)].

8 ADVERSE REACTIONS AND MEDICATION ERRORS REPORTING REQUIREMENTS AND INSTRUCTIONS
Clinical trials evaluating the safety of sotrovimab are ongoing [see Overall Safety Summary (6)].

The prescribing healthcare provider and/or the provider’s designee is/are responsible for the mandatory reporting of all serious adverse events* and medication errors potentially related to sotrovimab within 7 calendar days from the healthcare provider’s awareness of the event, using FDA Form 3500 (for information on how to access this form, see below). The FDA requires that such reports, using FDA Form 3500, include the following:

- Patient demographics and baseline characteristics (e.g., patient identifier, age or date of birth, gender, weight, ethnicity, and race)
- A statement "Sotrovimab use for COVID-19 under Emergency Use Authorization (EUA)” under the “Describe Event, Problem, or Product Use/Medication Error” heading
- Information about the serious adverse event or medication error (e.g., signs and symptoms, test/laboratory data, complications, timing of drug initiation in relation to the occurrence of the event, duration of the event, treatments required to mitigate the event, evidence of event improvement/disappearance after stopping or reducing the dosage, evidence of event
reappearance after reintroduction, clinical outcomes)

- Patient’s preexisting medical conditions and use of concomitant products
- Information about the product (e.g., dosage, route of administration, NDC #)

Submit adverse event and medication error reports, using Form 3500, to FDA MedWatch using one of the following methods:

- Complete and submit the report online at www.fda.gov/medwatch/report.htm, or
- Complete and submit a postage-paid FDA Form 3500 (https://www.fda.gov/media/76299/download) and return by:
  - Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
  - Fax (1-800-FDA-0178), or
- Call 1-800-FDA-1088 to request a reporting form.
- In addition, please provide a copy of all FDA MedWatch forms to:
  GlaxoSmithKline, Global Safety
  Fax: 919-287-2902
  Email: WW.GSKAEReportingUS@gsk.com
  Or call the GSK COVID Contact Center at 1-866-GSK-COVID (866-475-2684) to report adverse events.

The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory responses to requests from FDA for information about adverse events and medication errors following receipt of sotrovimab.

*Serious Adverse Events are defined as:

- death;
- a life-threatening adverse event;
- inpatient hospitalization or prolongation of existing hospitalization;
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
- a congenital anomaly/birth defect;
- other important medical event, which may require a medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly.

**IMPORTANT:** When reporting adverse events or medication errors to MedWatch, please complete the entire form with detailed information. It is important that the information reported to FDA be as detailed and complete as possible. Information to include:

- Patient demographics (e.g., patient initials, date of birth)
• Pertinent medical history
• Pertinent details regarding admission and course of illness
• Concomitant medications
• Timing of adverse event(s) in relationship to administration of sotrovimab
• Pertinent laboratory and virology information
• Outcome of the event and any additional follow-up information if it is available at the time of the MedWatch report. Subsequent reporting of follow-up information should be completed if additional details become available.

The following steps are highlighted to provide the necessary information for safety tracking:

• In section A, box 1, provide the patient’s initials in the Patient Identifier
• In section A, box 2, provide the patient’s date of birth
• In section B, box 5, description of the event:
  o Write “Sotrovimab use for COVID-19 under Emergency Use Authorization (EUA)” as the first line
  o Provide a detailed report of medication error and/or adverse event. It is important to provide detailed information regarding the patient and adverse event/medication error for ongoing safety evaluation of this unapproved drug. Please see information to include listed above.
• In section G, box 1, name and address:
  o Provide the name and contact information of the prescribing healthcare provider or institutional designee who is responsible for the report.
  o Provide the address of the treating institution (NOT the healthcare provider’s office address).

9 OTHER REPORTING REQUIREMENTS
Healthcare facilities and providers will report therapeutics information and utilization data as directed by the U.S. Department of Health and Human Services.

10 DRUG INTERACTIONS
Clinical drug-drug interaction studies have not been performed with sotrovimab. Sotrovimab is not renally excreted or metabolized by cytochrome P450 (CYP) enzymes; therefore, interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of CYP enzymes are unlikely.
11  USE IN SPECIFIC POPULATIONS

11.1  Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to sotrovimab during pregnancy. Pregnant and recently pregnant individuals can go to https://covid-pr.pregistry.com to enroll or call 1-800-616-3791 to obtain information about the registry.

Risk Summary

There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus. There are maternal and fetal risks associated with untreated COVID-19 in pregnancy (see Clinical Considerations).

Nonclinical reproductive toxicity studies have not been conducted with sotrovimab. In a cross-reactive binding assay using a protein array enriched for human embryofetal proteins, no off-target binding was detected for sotrovimab. Since sotrovimab is a recombinant human immunoglobulin G (IgG) containing the LS modification in the Fc domain, it has the potential for placental transfer from the mother to the developing fetus. The potential treatment benefit or risk of placental transfer of sotrovimab to the developing fetus is not known.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryo-Fetal Risk: COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death.

11.2  Lactation

Risk Summary

There are no available data on the presence of sotrovimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for sotrovimab and any potential adverse effects on the breastfed infant from sotrovimab or from the underlying maternal condition. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.
11.3 Pediatric Use
Sotrovimab is not authorized for use in pediatric patients under 12 years of age or weighing less than 40 kg. The safety and effectiveness of sotrovimab have not been assessed in pediatric patients. The recommended dosing regimen in patients 12 years to less than 18 years of age, weighing at least 40 kg, is expected to result in comparable serum exposures of sotrovimab as those observed in adults.

11.4 Geriatric Use
Of the 528 subjects randomized to receive sotrovimab in COMET-ICE, 20% were 65 years of age and older and 11% were over 70 years of age. Of the 378 subjects in the primary analysis population receiving sotrovimab in COMET-TAIL, 25% were 65 years of age or older and 8% were over 75 years of age. The difference in pharmacokinetics (PK) of sotrovimab in geriatric patients compared to younger patients has not been quantified.

11.5 Renal Impairment
No clinical trials have been conducted to evaluate the effects of renal impairment on the PK of sotrovimab. Sotrovimab is not eliminated intact in the urine, thus renal impairment is not expected to affect the exposure of sotrovimab.

11.6 Hepatic Impairment
No clinical trials have been conducted to evaluate the effects of hepatic impairment on the PK of sotrovimab. The impact of hepatic impairment on the PK of sotrovimab is unknown.

12 OVERDOSAGE
There is no human experience of acute overdosage with sotrovimab.

There is no specific treatment for an overdose with sotrovimab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

13 PRODUCT DESCRIPTION
Sotrovimab is a human immunoglobulin G-1 (IgG1-kappa) monoclonal antibody consisting of 2 identical light chain (LC) polypeptides composed of 214 amino acids each and 2 identical heavy chain (HC) polypeptides, each composed of 457 amino acids. Sotrovimab is produced by a Chinese Hamster Ovary cell line and has a molecular weight of approximately 149 kDa.

Sotrovimab injection is a sterile, preservative-free, clear, colorless or yellow to brown solution supplied in a single-dose vial for IV infusion after dilution.

Each mL contains sotrovimab (62.5 mg), L-histidine (1.51 mg), L-histidine monohydrochloride (2.15 mg), L-methionine (0.75 mg), polysorbate 80 (0.4 mg), and sucrose (70 mg). The solution of sotrovimab has a pH of 6.0.
14 CLINICAL PHARMACOLOGY

14.1 Mechanism of Action

Sotrovimab is a recombinant human IgG1-kappa mAb that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2 with a dissociation constant $K_D = 0.21$ nM) but does not compete with human ACE2 receptor binding (IC$_{50}$ value >33.6 nM [5 µg/mL]). Sotrovimab inhibits an undefined step that occurs after virus attachment and prior to fusion of the viral and cell membranes. The Fc domain of sotrovimab includes M428L and N434S amino acid substitutions (LS modification) that extend antibody half-life, but do not impact wild-type Fc-mediated effector functions in cell culture.

14.2 Pharmacokinetics

A summary of PK parameters following a single 500-mg IV infusion is presented in Table 1:

<table>
<thead>
<tr>
<th>PK Parameter$^a$</th>
<th>Sotrovimab (500 mg IV)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$$^b$, µg/mL</td>
<td>143 (34.5)</td>
<td>102</td>
</tr>
<tr>
<td>$C_{\text{D29}}$$^b$, µg/mL</td>
<td>40.7 (40.3)</td>
<td>135</td>
</tr>
<tr>
<td>AUC$_{\text{D1-29}}$$^c$, day*µg/mL</td>
<td>1410 (25.6)</td>
<td>20</td>
</tr>
</tbody>
</table>

$^a$ Parameters are reported as geometric mean (%CV$^b$).

$^b$ $C_{\text{max}}$ (end of infusion) and $C_{\text{D29}}$ (serum sotrovimab concentration on Study Day 29) estimates are based on cumulative intensive and sparse PK data available to date from the lead and expansion phases of COMET-PEAK B and C.

$^c$ AUC$_{\text{D1-29}}$ (area under the curve from Study Day 1 to 29) estimates are based on noncompartmental analyses of intensive PK from the Lead-in Phases of COMET-PEAK B and C.

Specific Populations

The effect of different covariates (e.g., age, sex, race, body weight, disease severity, hepatic impairment) on the PK of sotrovimab is unknown. Renal impairment is not expected to impact the PK of sotrovimab since mAbs with molecular weight >69 kDa do not undergo renal elimination. Similarly, dialysis is not expected to impact the PK of sotrovimab.

15 MICROBIOLOGY/RESISTANCE INFORMATION

Antiviral Activity

The neutralization activity of sotrovimab against SARS-CoV-2 (isolate USA WA1/2020) was measured in a concentration response model using cultured Vero E6 cells. Sotrovimab neutralized SARS-CoV-2 with an average EC$_{50}$ value of 0.67 nM (100.1 ng/mL) and an average EC$_{90}$ value of 1.2 nM (186.3 ng/mL).

Sotrovimab demonstrated cell culture FcγR activation using Jurkat reporter cells expressing FcγRIIa (low-affinity R131 and high affinity H131 alleles), FcγRIIIa (low-affinity F158 and
high-affinity V158 alleles) and FcγRIIb. Sotrovimab exhibited antibody-dependent cell-mediated cytotoxicity (ADCC) in cell culture using isolated human natural killer (NK) cells following engagement with target cells expressing spike protein. Sotrovimab also elicited antibody-dependent cellular phagocytosis (ADCP) in cell-based assays using CD14+ monocytes targeting cells expressing spike protein.

**Antibody Dependent Enhancement (ADE) of Infection**

The risk that sotrovimab could mediate viral uptake and replication by immune cells was studied in U937 cells, primary human monocyctic dendritic cells, and peripheral blood mononuclear cells. This experiment did not demonstrate productive viral infection in immune cells exposed to SARS-CoV-2 in the presence of concentrations of sotrovimab from 1-fold down to 1000-fold below the EC50 value.

The potential for ADE was also evaluated in a hamster model of SARS-CoV-2 using sotrovimab. Intraperitoneal administration prior to inoculation resulted in a dose-dependent improvement in all measured outcomes (body weight, total viral RNA in the lungs, or infectious virus levels based on TCID50 measurements). No evidence of enhancement of disease was observed at any dose evaluated, including sub-neutralizing doses down to 0.05 mg/kg.

**Antiviral Resistance**

There is a potential risk of treatment failure due to the development of viral variants that are resistant to sotrovimab. Prescribing healthcare providers should choose an authorized therapeutic option with activity against circulating SARS-CoV-2 variants in their state. SARS-CoV-2 variant frequency data for states and jurisdictions can be accessed on the CDC website.

Spike protein amino acid substitution E340A emerged in cell culture selection of resistant virus and had a >100-fold reduction in activity in a pseudotyped virus-like particle (VLP) assay. This substitution is in the conserved epitope of sotrovimab, which is comprised of 23 amino acids. A pseudotyped VLP assessment in cell culture showed that epitope amino acid substitutions P337H/K/L/R/T, E340A/K/G/Q/V, T345P, K356T, and L441N conferred reduced susceptibility to sotrovimab based on observed fold-increase in EC50 value shown in parentheses: P337H (5.13), P337K (>304), P337L (>192), P337R (>192), P337T (10.62), E340A (>100), E340G (18.21), E340K (>297), E340Q (>50), E340V (>200), T345P (225), K356T (5.90), and L441N (72). The presence of the highly prevalent D614G substitution, either alone or in combination, did not alter neutralization of sotrovimab. Pseudotyped VLP assessments indicate that sotrovimab retains activity against the B.1.1.7 (Alpha, UK origin: H69-, V70-, Y144-, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H; 2.3-fold change in EC50 value), B.1.351 (Beta, South Africa origin: L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V; 0.6-fold change in EC50 value), P.1 (Gamma, Brazil origin: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F; 0.35-fold change in EC50 value), B.1.427/B.1.429 (Epsilon, California origin: S13I, W152C, L452R, D614G; 0.7-fold change in


It is not known how pseudotyped VLPs or authentic SARS-CoV-2 neutralization susceptibility data correlate with clinical outcome.

### Table 2. Sotrovimab Pseudotyped Virus-Like Particle Neutralization Data for SARS-CoV-2 Variants

<table>
<thead>
<tr>
<th>Lineage with Spike Protein Substitution</th>
<th>Country First Identified</th>
<th>WHO Nomenclature</th>
<th>Key Substitutions Tested</th>
<th>Fold Reduction in Susceptibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.1.7</td>
<td>UK</td>
<td>Alpha</td>
<td>N501Y^a</td>
<td>No change^b</td>
</tr>
<tr>
<td>B.1.351</td>
<td>South Africa</td>
<td>Beta</td>
<td>K417N+E484K+N501Y^c</td>
<td>No change^b</td>
</tr>
<tr>
<td>P.1</td>
<td>Brazil</td>
<td>Gamma</td>
<td>K417T+E484K+N501Y^d</td>
<td>No change^b</td>
</tr>
<tr>
<td>B.1.427/B.1.429</td>
<td>USA (California)</td>
<td>Epsilon</td>
<td>L452R^e</td>
<td>No change^b</td>
</tr>
<tr>
<td>B.1.526*</td>
<td>USA (New York)</td>
<td>Iota</td>
<td>E484K^g</td>
<td>No change^b</td>
</tr>
<tr>
<td>Strain</td>
<td>Country</td>
<td>Variant</td>
<td>Changes</td>
<td>Effect</td>
</tr>
<tr>
<td>-------------</td>
<td>----------</td>
<td>---------</td>
<td>----------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>B.1.617.1</td>
<td>India</td>
<td>Kappa</td>
<td>L452R+E484Q</td>
<td>No change</td>
</tr>
<tr>
<td>AY.1/AY.2</td>
<td>India</td>
<td>Delta</td>
<td>L452R+T478K</td>
<td>No change</td>
</tr>
<tr>
<td>C.37</td>
<td>Peru</td>
<td>Lambda</td>
<td>L452Q+F490S</td>
<td>No change</td>
</tr>
<tr>
<td>B.1.621</td>
<td>Colombia</td>
<td>Mu</td>
<td>R346K+E484K+N501Y</td>
<td>No change</td>
</tr>
<tr>
<td>B.1.617.2/AY.4.2</td>
<td>India</td>
<td>Delta</td>
<td>L452R+T478K+K417N</td>
<td>No change</td>
</tr>
<tr>
<td>B.1.1.529/BA.1</td>
<td>South Africa</td>
<td>Omicron</td>
<td>G339D+S371L+S373P+S375F+K417N+N440K+G446S+S477N+T478K+E484A+Q493R+G496S+Q498R+N501Y+Y505H</td>
<td>No change</td>
</tr>
<tr>
<td>B.1.1.529/BA.1.1</td>
<td>South Africa</td>
<td>Omicron</td>
<td>G339D+R346K+S371L+S373P+S375F+K417N+N440K+G446S+S477N+T478K+E484A+Q493R+G496S+Q498R+N501Y+Y505H</td>
<td>No change</td>
</tr>
</tbody>
</table>

**a** Pseudotyped VSV-luc expressing variant spike protein was tested. The following changes from wild-type spike protein are found in the variant: del69-70, del144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H.

**b** No change: <5-fold reduction in susceptibility.

**c** Pseudotyped VSV-luc expressing variant spike protein was tested. The following changes from wild-type spike protein are found in the variant: L18F, D80A, D215G, R246I, K417N, E484K, N501Y, A701V.

**d** Pseudotyped VSV-luc expressing variant spike protein was tested. The following changes from wild-type spike protein are found in the variant: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F.

**e** Pseudotyped VSV-luc expressing variant spike protein was tested. The following changes from wild-type spike protein are found in the variant: S13I, W152C, L452R, D614G.

**f** Not all isolates of the New York lineage harbor the E484K substitution (as of February 2021).

**g** Pseudotyped VSV-luc expressing variant spike protein was tested. The following changes from wild-type spike protein are found in the variant: L5F, T95I, D253G, E484K, D614G, A701V.

**h** Pseudotyped VSV-luc expressing variant spike protein was tested. The following changes from wild-type spike protein are found in the variant: T95I, G142D, E154K, L452R, E484Q.
D614G, P681R, Q1071H.


Pseudotyped VSV-luc expressing variant spike protein was tested. The following changes from wild-type spike protein are found in the variant: G75V, T76I, del246-252, L452Q, F490S, T859N.

Pseudotyped VSV-luc expressing variant spike protein was tested. The following changes from wild-type spike protein are found in the variant: T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H, D950N.


Clinical relevance of the 16-fold reduction in susceptibility is unknown.

Microneutralization data using authentic SARS-CoV-2 variant viruses indicate that sotrovimab retains activity against the B.1.1.7 (Alpha, UK origin; 3-fold change in EC₅₀ value), B.1.351 (Beta, South Africa origin; 1.2-fold change in EC₅₀ value), P.1 (Gamma, Brazil origin; 1.6-fold change in EC₅₀ value), B.1.617.1 (Kappa, India origin; 0.9-fold change in EC₅₀ value), and B.1.617.2 (Delta, India origin; 0.4-fold change in EC₅₀ value) variants (Table 3).
Table 3. Sotrovimab Authentic SARS-CoV-2 Neutralization Data for SARS-CoV-2 Variants

<table>
<thead>
<tr>
<th>SARS-CoV-2 Lineage</th>
<th>Country First Identified</th>
<th>WHO Nomenclature</th>
<th>Key Substitutions&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Fold Reduction in Susceptibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.1.7</td>
<td>UK</td>
<td>Alpha</td>
<td>N501Y</td>
<td>No change&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>B.1.351</td>
<td>South Africa</td>
<td>Beta</td>
<td>K417N+E484K+N501Y</td>
<td>No change&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>P.1</td>
<td>Brazil</td>
<td>Gamma</td>
<td>K417T+E484K+N501Y</td>
<td>No change&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>B.1.617.1</td>
<td>India</td>
<td>Kappa</td>
<td>L452R+E484Q</td>
<td>No change&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>B.1.617.2</td>
<td>India</td>
<td>Delta</td>
<td>L452R+T478K</td>
<td>No change&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> For variants with more than one substitution of concern, only the one(s) with the greatest impact on activity is (are) listed.

<sup>b</sup> No change: <5-fold reduction in susceptibility.

Limited nucleotide sequencing data from a total of 539 COMET-ICE subjects indicated that 36 subjects (16 treated with placebo and 20 treated with sotrovimab) carried the B.1.1.7 (Alpha, UK origin) variant. Four subjects (2 treated with placebo and 2 treated with sotrovimab) carried the N501Y substitution. Thirty-one subjects (19 treated with placebo and 12 treated with sotrovimab) carried the B.1.427/B.1.429 (Epsilon, California origin) variant. Eight additional subjects carried the L452R substitution (6 treated with placebo and 2 treated with sotrovimab). Eleven subjects carried the P.1 (Gamma, Brazil origin) variant (3 treated with placebo and 8 treated with sotrovimab). Three subjects carried the B.1.526 (Iota, New York origin) variant with the E484K substitution (2 treated with placebo and 1 treated with sotrovimab), while 9 subjects (4 treated with placebo and 5 treated with sotrovimab) carried the S477N substitution that has been associated with the B.1.526 (Iota, New York origin) variant. Additionally, 10 subjects carried the E484K substitution (4 treated with placebo and 6 treated with sotrovimab), 2 carried the S494P substitution (1 treated with placebo and 1 treated with sotrovimab), and 3 carried the S494P substitution with the N501Y substitution (2 treated with placebo and 1 treated with sotrovimab). Two subjects in the group receiving sotrovimab (1 carrying the B.1.427/B.1.429 [Epsilon, California origin] variant and 1 carrying the B.1.1.7 [Alpha, UK origin] variant) progressed to hospitalization. Four subjects in the placebo group (2 carrying the E484K substitution, 1 carrying the P.1 [Gamma, Brazil origin] variant, and 1 carrying the B.1.1.7 [Alpha, UK origin] variant) progressed to hospitalization. None of the subjects with currently available baseline sequences carried the full complement of substitutions characteristic of the B.1.351 (Beta, South Africa origin) or B.1.617 (Delta, India origin) variants.

In COMET-ICE, post-baseline epitope substitutions were detected in 20 subjects in the cohort receiving sotrovimab (spike protein substitutions P337L/E340K [49.4%/54.8% allele frequency]; E340A [99.0%]; E340K [5 subjects: 8.0% to 99.9%]; E340V [73.1%]; A344V [6.2%]; R346G [5.2%]; K356R [7.5%]; S359G [2 subjects: 12.2% and 8.3%]); C361T [7 subjects: 5.0% to 15.7%]. Of the substitutions detected at baseline and post-baseline, L335F, L335S, P337L,
G339C, E340A, E340K, A344V, R346G, R346I, K356N, K356R, R357I, I358V and S359G substitutions have been assessed phenotypically using a pseudotyped VLP system. P337L, E340A, and E340K substitutions confer reduced susceptibility to sotrovimab (>100-fold change in EC\textsubscript{50} value). Sotrovimab retains activity against L335F (0.8-fold change in EC\textsubscript{50} value), L335S (0.9-fold change in EC\textsubscript{50} value), G339C (1.2-fold change in EC\textsubscript{50} value), A344V (1.1-fold change in EC\textsubscript{50} value), R346G (0.9-fold change in EC\textsubscript{50} value), R346I (1.7-fold change in EC\textsubscript{50} value), K356N (1.1-fold change in EC\textsubscript{50} value), K356R (0.8-fold change in EC\textsubscript{50} value), R357I (1-fold change in EC\textsubscript{50} value), I358V (0.7-fold change in EC\textsubscript{50} value), and S359G (0.8-fold change in EC\textsubscript{50} value) substitutions. The clinical impact of these substitutions is not yet known.

Data collection and analysis is still ongoing.

**Immune Response Attenuation**

There is a theoretical risk that antibody administration may attenuate the endogenous immune response to SARS-CoV-2 and make patients more susceptible to re-infection.

**16 NONCLINICAL TOXICOLOGY**

Carcinogenesis, mutagenesis, and reproductive toxicology studies with sotrovimab have not been conducted.

In a toxicology study in monkeys, sotrovimab had no adverse effects when administered intravenously.

In tissue cross-reactivity studies using human and monkey adult tissues, no binding of clinical concern was detected for sotrovimab.

In a cross-reactive binding assay using a protein array enriched for human embryofetal proteins, no off-target binding was detected for sotrovimab.

**17 ANIMAL PHARMACOLOGIC AND EFFICACY DATA**

In a Syrian Golden hamster model of SARS-CoV-2 infection, antiviral activity was demonstrated using a single dose of sotrovimab which was administered intraperitoneally at 24- or 48-hours prior to infection. Animals receiving 5 mg/kg or more of the antibody showed a significant improvement in body weight loss and significantly decreased total lung SARS-CoV-2 viral RNA compared to vehicle only and control antibody-treated animals. Levels of virus in the lung (as measured by TCID\textsubscript{50}) were significantly decreased versus controls in hamsters receiving 0.5 mg/kg or more of the antibody.

Protection was also observed in the Syrian Golden hamster model using the SARS-CoV-2 B.1.351 (Beta, South Africa origin) variant. Significant reductions in total and replication competent virus were observed on Day 4 post-infection in animals receiving a single intraperitoneal dose of 0.5, 2, 5, or 15 mg/kg sotrovimab compared to isotype control antibody-treated animals.
The clinical data supporting this EUA are based on the analysis of the Phase 1/2/3 COMET-ICE trial (NCT04545060) with supporting data from the Phase 3 COMET-TAIL trial (NCT04913675).

**COMET-ICE Trial**

COMET-ICE was a, randomized, multi-center, double-blind, placebo-controlled trial studying sotrovimab for the treatment of subjects with mild-to-moderate COVID-19 (subjects with COVID-19 symptoms who are not hospitalized). Eligible subjects were 18 years of age and older with at least one of the following comorbidities: diabetes, obesity (BMI >30), chronic kidney disease, congestive heart failure, chronic obstructive pulmonary disease, or moderate to severe asthma; or were 55 years of age and older regardless of comorbidities. The trial included symptomatic subjects with SARS-CoV-2 infection as confirmed by local laboratory tests and/or point of care tests and symptom onset within 5 days of enrollment. Subjects with severe COVID-19 requiring supplemental oxygen or hospitalization and severely immunocompromised subjects were excluded from the trial.

A total of 1,057 eligible subjects were randomized to receive a single 500-mg infusion of sotrovimab (n = 528) or placebo (n = 529) over 1 hour (Intent to Treat [ITT] population at Day 29). At baseline, the median age was 53 years (range:17 to 96); 20% of subjects were 65 years of age or older and 11% were over 70 years of age; 46% of subjects were male; 87% were White, 8% Black or African American, 4% Asian, 65% Hispanic or Latino. Fifty-nine percent of subjects received sotrovimab or placebo within 3 days of COVID-19 symptom onset and 41% within 4 to 5 days. The four most common pre-defined risk factors or comorbidities were obesity (63%), 55 years of age or older (47%), diabetes requiring medication (22%), and moderate-to-severe asthma (17%). Overall, baseline demographic and disease characteristics were well balanced between the treatment arms.

The primary endpoint, progression of COVID-19 at Day 29, was reduced by 79% (adjusted relative risk reduction) in recipients of sotrovimab versus placebo. Table 4 provides the results for the primary and key secondary endpoint of COMET-ICE.
Table 4. Efficacy Results in Adults with Mild-to-Moderate COVID-19 in COMET-ICE at Day 29

<table>
<thead>
<tr>
<th>Progression of COVID-19 (defined as hospitalization for &gt;24 hours for acute management of any illness or death from any cause) (Day 29)(^a)</th>
<th>Sotrovimab (n = 528)</th>
<th>Placebo (n = 529)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion (n, %)</td>
<td>6 (1.1%)</td>
<td>30 (5.7%)</td>
</tr>
<tr>
<td>Adjusted Relative Risk Reduction (95% CI)</td>
<td>79% (50%, 91%)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>All-cause mortality (up to Day 29)</th>
<th>Sotrovimab (n = 528)</th>
<th>Placebo (n = 529)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion (n, %)</td>
<td>0</td>
<td>2 (&lt;1%)</td>
</tr>
</tbody>
</table>

\(^a\) The determination of primary efficacy was based on a planned interim analysis of 583 subjects, which had similar findings to those seen in the full population above. The adjusted relative risk reduction was 85% with a 97.24% CI of (44%, 96%) and p-value = 0.002.

Within the subset of the ITT population who had a central laboratory confirmed, virologically quantifiable nasopharyngeal swab at Day 1 and Day 8 (\(n = 639\)), the mean decline from baseline in viral load at Day 8 was greater in subjects treated with sotrovimab (-2.610 \(\log_{10}\) copies/mL) compared to that in subjects treated with placebo (-2.358); mean difference = -0.251, 95% CI: (-0.415, -0.087).

**COMET-TAIL Trial**

COMET-TAIL was a randomized, multi-center, open label trial which evaluated the efficacy, safety, and tolerability of sotrovimab for the treatment of subjects with mild-to-moderate COVID-19 (subjects with COVID-19 symptoms who are not hospitalized). Eligible subjects were 12 years of age or older with at least one of the following comorbidities: diabetes, obesity (BMI \(\geq 85^{th}\) percentile for age/gender based on Centers for Disease Control and Prevention [CDC] growth charts for adolescents or BMI \(\geq 30\) for subjects \(\geq 18\) years old), chronic kidney disease, congenital heart disease, congestive heart failure (for subjects \(\geq 18\) years old), chronic lung diseases, sickle cell disease, neurodevelopmental disorders, immunosuppressive disease or receiving immunosuppressive medications, or chronic liver disease; or were 55 years of age or older regardless of comorbidities. The trial included symptomatic subjects with SARS-CoV-2 infection as confirmed by local laboratory tests and/or point of care tests and symptom onset within 7 days of enrollment. Subjects with severe COVID-19 requiring supplemental oxygen or hospitalization were excluded from the trial.

The ITT population consisted of 385 subjects randomized to receive a single 500-mg IV infusion of sotrovimab over 15 minutes. The primary analysis population, which excluded 7 subjects because they were fully vaccinated and immunocompetent (key inclusion/exclusion violation), consisted of 378 subjects.

In the primary analysis population at baseline, the median age was 51 years (range:15 to 90, including 2 subjects under 18 years); 25% of subjects were 65 years of age or older and 8% were
over 75 years of age; 42% of subjects were male; 96% were White and 4% were Black or African American; 83% were Hispanic or Latino. Forty-eight percent (48%) of subjects received sotrovimab within 3 days of COVID-19 symptom onset, 37% within 4 to 5 days, and 14% within 6 to 7 days. The four most common pre-defined risk factors or comorbidities were obesity (63%), 55 years of age or older (42%), chronic lung disease (16%), and diabetes requiring medication (13%).

In the primary analysis population, 5 (1.3%) of 378 subjects had progression to COVID-19 defined as hospitalization for >24 hours for acute management of any illness or death due to any cause through Day 29. No deaths were reported through Day 29.

19 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied
Sotrovimab injection 500 mg (62.5 mg/mL) is a sterile, preservative-free, clear, colorless or yellow to brown solution supplied in a carton containing one single-dose glass vial with a rubber vial stopper (not made with natural rubber latex) and a flip-off cap (NDC 0173-0901-86).

Storage and Handling
Sotrovimab is preservative-free. Discard unused portion.

Store unopened vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton. Do not freeze or shake. Protect from light.

The solution of sotrovimab in the vial is preservative-free and requires dilution prior to IV administration. The diluted infusion solution of sotrovimab should be administered immediately. If immediate administration is not possible, store the diluted infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) or up to 6 hours at room temperature (up to 25°C [up to 77°F]) including transportation and infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 15 minutes prior to administration.

20 PATIENT COUNSELING INFORMATION

Patients treated with sotrovimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines. Also, see “Fact Sheet for Patients, Parents, and Caregivers”.

Pregnancy Registry

Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in individuals exposed to sotrovimab during pregnancy [see Use in Specific Populations (11.1)].

21 CONTACT INFORMATION

For additional information visit www.sotrovimabinfo.com
If you have questions, please call the GSK COVID Contact Center at 1-866-GSK-COVID (866-475-2684).

Manufactured by GlaxoSmithKline LLC
Philadelphia, PA 19112, U.S. License No. 1727
Distributed by GlaxoSmithKline
Research Triangle Park, NC 27709
©2022 GSK group of companies or its licensor.
STR:XFS-HCP
Revised: February 2022